Compare Adaptive Biotechnologies Corp (ADPT) vs Firy Inc. (FIRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Firy Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Firy Inc. trades at $9.05 (market cap $143.59M). The key difference: Adaptive Biotechnologies Corp is far larger — about 23.2× Firy Inc.'s market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | FIRY | |
|---|---|---|
Market Cap | $3.33B | $143.59M |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $12.45 |
52-Week Low | $10.24 | $2.28 |
Enterprise Value | $3.19B | $87.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FIRY, formerly Skillz Inc., trades at $9.20, down 5.54% today, amid a recent rebranding and mixed quarterly results. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; the company's cost structure and profitability challenges pose significant risks, offset by potential from legal victories and strategic shifts. Analysts are mostly neutral, with 60% hold ratings. Investors should weigh the high execution risk against any turnaround prospects in the competitive mobile gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
